fotemustine has been researched along with Anemia in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baruchel, S; Bouffet, E; Gammon, J; Grant, RM; Hargrave, DR; Tariq, N | 1 |
Allen, R; Berille, J; Rudd, R; Souhami, RL; Spiro, SG; Trask, C | 1 |
Boaziz, C; Coste, M; Haon, C; Raymond, E | 1 |
Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
1 review(s) available for fotemustine and Anemia
Article | Year |
---|---|
Logistic regression model of fotemustine toxicity combining independent phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Female; Humans; Leukopenia; Logistic Models; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia | 1996 |
3 trial(s) available for fotemustine and Anemia
Article | Year |
---|---|
Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Topics: Adolescent; Anemia; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Female; Humans; Infant; Injections, Intravenous; Male; Medulloblastoma; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Sarcoma; Thrombocytopenia; Treatment Outcome | 2002 |
Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Thrombocytopenia | 1994 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |